Clinical Trial Update: Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy

View source ↗

Summary

Post-marketing surveillance study of nintedanib in Indian patients with non-small cell lung cancer after first-line therapy completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Non-small Cell Lung Cancer | Status: COMPLETED | Results posted: 2024-03-25